4.4 Article

PAX6 dosage effects on comeal development, growth, and wound healing

Journal

DEVELOPMENTAL DYNAMICS
Volume 237, Issue 5, Pages 1295-1306

Publisher

WILEY-LISS
DOI: 10.1002/dvdy.21528

Keywords

cornea; Pax6; gene dosage; anterior segment; wound healing

Funding

  1. BBSRC [BB/E015840/1] Funding Source: UKRI
  2. Biotechnology and Biological Sciences Research Council [BB/E015840/1] Funding Source: researchfish
  3. Biotechnology and Biological Sciences Research Council [BB/E0158401/1, BB/E015840/1] Funding Source: Medline
  4. Wellcome Trust [074127] Funding Source: Medline

Ask authors/readers for more resources

The requirement for correct dosage of the transcription factor Pax6 during corneal growth and development was investigated using the Pax6-overexpressing (PAX77) transgenic mouse. Transgenics had a microcornea phenotype due to failure of postnatal growth, associated with reduction in the number of cells layers in the corneal epithelium. Cell cycle progression was monitored using bromodeoxyuridine, p63, cyclin E, and phosphohistone-3 labeling: proliferation rates were higher in PAX77(+) than wild-type, without a concomitant increase in apoptosis. Hence, failure of proliferation did not underlie microcornea. PAX77(+) corneal epithelia had reduced levels of cytokeratin-12, and exhibited severe wound healing delay that, in contrast to Pax6(+/-) mice, could not be modulated by exogenous growth factors. PAX77(+) lenses showed partial failure of lens fiber differentiation. The data demonstrate that anterior eye development is very sensitive to Pax6 dosage. Although there are similarities between the eye phenotype of Pax6 heterozygotes and overexpressing mice, there are also striking differences.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available